tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Finn L et al. | Epstein-Barr virus infections in children after transplantation of the small intestine. | 1998 | Am. J. Surg. Pathol. | pmid:9500771 |
| Randhawa PS et al. | The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. | 1993 | Am. J. Surg. Pathol. | pmid:7680544 |
| Minervini MI et al. | Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). | 2000 | Am. J. Surg. Pathol. | pmid:10757402 |
| Randhawa PS et al. | Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. | 1996 | Am. J. Surg. Pathol. | pmid:8772784 |
| Cosio FG and Larson TS | Cardiovascular disease after transplantation: do we know all of the variables? | 2003 | Am. J. Transplant. | pmid:12859523 |
| Krämer BK et al. | Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. | 2003 | Am. J. Transplant. | pmid:12859533 |
| Ciancio G et al. | The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. | 2003 | Am. J. Transplant. | pmid:12859538 |
| Singh K et al. | Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. | 2014 | Am. J. Transplant. | pmid:25359003 |
| Tang Q | Pharmacokinetics of therapeutic Tregs. | 2014 | Am. J. Transplant. | pmid:25358900 |
| Wen X et al. | Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27137884 |
| Sikma MA et al. | Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. | 2015 | Am. J. Transplant. | pmid:26053114 |
| de Fontbrune FS et al. | Veno-occlusive disease of the liver after lung transplantation. | 2007 | Am. J. Transplant. | pmid:17697264 |
| Abdelmalek MF et al. | Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. | 2012 | Am. J. Transplant. | pmid:22233522 |
| Boudjema K et al. | Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. | 2011 | Am. J. Transplant. | pmid:21466650 |
| Gupta G et al. | Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. | 2015 | Am. J. Transplant. | pmid:25988397 |
| Suszynski TM et al. | Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. | 2013 | Am. J. Transplant. | pmid:23432755 |
| Damon C et al. | Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. | 2017 | Am. J. Transplant. | pmid:27597269 |
| Ferguson R et al. | Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21114656 |
| Klintmalm GB | Immunosuppression, generic drugs and the FDA. | 2011 | Am. J. Transplant. | pmid:21794082 |
| Böger CA et al. | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. | 2006 | Am. J. Transplant. | pmid:16889550 |
| Forns X and Navasa M | Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. | 2011 | Am. J. Transplant. | pmid:21797970 |
| Tan HP et al. | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. | 2006 | Am. J. Transplant. | pmid:16889606 |
| Wlodarczyk Z et al. | Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. | 2009 | Am. J. Transplant. | pmid:19681813 |
| Chisholm-Burns MA et al. | Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681814 |
| Schold JD and Kaplan B | AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681827 |
| Busque S et al. | Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. | 2009 | Am. J. Transplant. | pmid:19660021 |
| Gao R et al. | Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. | 2007 | Am. J. Transplant. | pmid:17391142 |
| Tremblay S et al. | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. | 2017 | Am. J. Transplant. | pmid:27340950 |
| De Simone P et al. | Everolimus with reduced tacrolimus in liver transplantation. | 2013 | Am. J. Transplant. | pmid:23601137 |
| Luther P and Baldwin D | Pioglitazone in the management of diabetes mellitus after transplantation. | 2004 | Am. J. Transplant. | pmid:15575920 |
| Cherukuri A et al. | An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. | 2012 | Am. J. Transplant. | pmid:22390816 |
| Pascher A et al. | Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. | 2015 | Am. J. Transplant. | pmid:25677074 |
| Chen G et al. | A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. | 2006 | Am. J. Transplant. | pmid:16539628 |
| Knechtle SJ et al. | Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. | 2009 | Am. J. Transplant. | pmid:19344431 |
| Bahra M et al. | MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. | 2005 | Am. J. Transplant. | pmid:15644002 |
| van Hooff JP et al. | Glucose metabolic disorder after transplantation. | 2007 | Am. J. Transplant. | pmid:17511670 |
| Grinyo JM et al. | Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15268733 |
| Schussler T et al. | Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. | 2004 | Am. J. Transplant. | pmid:15268744 |
| Toso C et al. | Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. | 2006 | Am. J. Transplant. | pmid:16611343 |
| Lacaille F et al. | Severe dysimmune cytopenia in children treated with tacrolimus after organ transplantation. | 2006 | Am. J. Transplant. | pmid:16611346 |
| Tedesco-Silva H et al. | Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. | 2015 | Am. J. Transplant. | pmid:25988935 |
| Pech T et al. | Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. | 2012 | Am. J. Transplant. | pmid:22974463 |
| Kaplan B and Kirk AD | Tacrolimus and sirolimus: when bad things happen to good drugs. | 2006 | Am. J. Transplant. | pmid:16827845 |
| McAlister VC et al. | Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. | 2006 | Am. J. Transplant. | pmid:16827858 |
| Gallon L et al. | Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. | 2006 | Am. J. Transplant. | pmid:16827862 |
| Grenda R et al. | A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. | 2006 | Am. J. Transplant. | pmid:16827869 |
| Vanhove T et al. | High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. | 2016 | Am. J. Transplant. | pmid:27013142 |
| Fujishiro J et al. | Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. | 2010 | Am. J. Transplant. | pmid:20642681 |
| Martinez F et al. | High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. | 2010 | Am. J. Transplant. | pmid:20642691 |
| Brennan DC et al. | Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. | 2005 | Am. J. Transplant. | pmid:15707414 |